Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Thrombocythemia, Essential 2Polycythemia Vera 2Skin Neoplasms 1Philadelphia Chromosome 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia 1Infections 1Hepatitis C 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Gemcitabine 43pembrolizumab 36Paclitaxel 36Nivolumab 31Docetaxel 29Capecitabine 29Bevacizumab 29Oxaliplatin 28Fluorouracil 28Cisplatin 26Leucovorin 24Cyclophosphamide 23Radiosurgery 20Irinotecan 20Carboplatin 20aldesleukin 19Cetuximab 19Interleukin-2 16fludarabine phosphate 15fludarabine 15Pemetrexed 15Trastuzumab 14Magnetic Resonance Spectroscopy 14Ipilimumab 14Fulvestrant 14130-nm albumin-bound paclitaxel 14Prednisone 13Everolimus 13Radiotherapy 12Panitumumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm Metastasis × peginterferon alfa-2a × Clear all
NCT02218164 2022-10-07

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
8 enrolled 11 charts
Dermatologic

Carcinoma, Squamous Cell, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡